JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.04B |
| 2 |
Truist Financial
TFC
|
+$964M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$909M |
| 4 |
Texas Instruments
TXN
|
+$800M |
| 5 |
Johnson & Johnson
JNJ
|
+$783M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$1.43B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$1.21B |
| 3 |
STI
SunTrust Banks, Inc.
STI
|
+$987M |
| 4 |
Microsoft
MSFT
|
+$980M |
| 5 |
CELG
Celgene Corp
CELG
|
+$929M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.95% |
| 2 | Financials | 11.95% |
| 3 | Healthcare | 9.46% |
| 4 | Consumer Discretionary | 8.62% |
| 5 | Industrials | 6.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARQL
4176
PUT
DELISTED
Arqule Inc
ARQL
| $401K | ﹤0.01% |
+20,100
| New | +$233K |
|
4177
State Street SPDR Portfolio Mortgage Backed Bond ETF
SPMB
$7.05B
| $400K | ﹤0.01% |
15,328
| – | – |
|
4178
Kimbell Royalty Partners
KRP
$1.5B
| $399K | ﹤0.01% |
23,470
+4,470
| +24% | +$66.5K |
|
|
SHYF
4179
DELISTED
The Shyft Group
SHYF
| $399K | ﹤0.01% |
22,055
-23,409
| -51% | -$391K |
|
4180
Veru
VERU
$46.7M
| $398K | ﹤0.01% |
11,879
+1,051
| +10% | +$23.5K |
|
4181
ProShares VIX Short-Term Futures ETF
VIXY
$189M
| $398K | ﹤0.01% |
400
+257
| +180% | +$320K |
|
|
TEN
4182
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $398K | ﹤0.01% |
30,375
-159,923
| -84% | -$2.1M |
|
4183
Rigel Pharmaceuticals
RIGL
$782M
| $397K | ﹤0.01% |
18,563
+13,048
| +237% | +$269K |
|
|
EBIX
4184
DELISTED
Ebix Inc
EBIX
| $396K | ﹤0.01% |
11,879
+954
| +9% | +$35.3K |
|
4185
Johnson Outdoors
JOUT
$499M
| $395K | ﹤0.01% |
5,154
-21,933
| -81% | -$1.43M |
|
|
STXB
4186
DELISTED
Spirit of Texas Bancshares, Inc. Common Stock
STXB
| $395K | ﹤0.01% |
17,153
+9,079
| +112% | +$200K |
|
4187
DMC Global
BOOM
$155M
| $394K | ﹤0.01% |
8,775
+2,649
| +43% | +$118K |
|
4188
MakeMyTrip
MMYT
$5.67B
| $393K | ﹤0.01% |
+17,164
| New | +$415K |
|
|
FOLD
4189
CALL
DELISTED
Amicus Therapeutics
FOLD
| $390K | ﹤0.01% |
+40,000
| New | +$366K |
|
|
FOLD
4190
PUT
DELISTED
Amicus Therapeutics
FOLD
| $390K | ﹤0.01% |
+40,000
| New | +$366K |
|
4191
Opko Health
OPK
$1.04B
| $389K | ﹤0.01% |
264,702
-744,844
| -74% | -$1.25M |
|
4192
Aclaris Therapeutics
ACRS
$860M
| $388K | ﹤0.01% |
205,468
-10,784
| -5% | -$17.9K |
|
|
NBIS
4193
PUT
Nebius Group N.V.
NBIS
$65.8B
| $387K | ﹤0.01% |
8,900
| – | – |
|
|
ODT
4194
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $385K | ﹤0.01% |
11,855
+8,011
| +208% | +$248K |
|
4195
SmartFinancial
SMBK
$898M
| $382K | ﹤0.01% |
16,142
-3,794
| -19% | -$83.5K |
|
4196
Anika Therapeutics
ANIK
$295M
| $380K | ﹤0.01% |
7,347
+748
| +11% | +$43.5K |
|
4197
AMES National
ATLO
$281M
| $380K | ﹤0.01% |
13,530
+9,816
| +264% | +$273K |
|
4198
Preformed Line Products
PLPC
$2.29B
| $379K | ﹤0.01% |
6,285
+3,194
| +103% | +$199K |
|
|
ITIC
4199
Investors Title Co
ITIC
$530M
| $377K | ﹤0.01% |
2,370
+1,087
| +85% | +$176K |
|
4200
CALL
Annaly Capital Management
NLY
$17.4B
| $377K | ﹤0.01% |
+10,000
| New | +$365K |
|
Similar funds
JP Morgan Chase's Q4 2019 Portfolio in Review
As of Q4 2019, JP Morgan Chase held 6,136 positions worth $536B, up 6.8% from $502B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q4 2019 filing shows 374 new, 2,295 increased, 2,258 reduced and 490 closed positions. Its largest new stake was XP: 4,912,590 shares worth $189M. The largest sale was Pfizer, an estimated $1.43B.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 13% a quarter earlier, followed by Financials and Healthcare.
- JP Morgan Chase's largest Q4 2019 buy was XP: 4,912,590 shares worth $189M.
- JP Morgan Chase added most to iShares 20+ Year Treasury Bond ETF in Q4 2019, an estimated $1.04B increase.
- JP Morgan Chase's biggest Q4 2019 reduction was Pfizer, cutting an estimated $1.43B.
- JP Morgan Chase fully exited SunTrust Banks, Inc. in Q4 2019, selling an estimated $987M.
- JP Morgan Chase's ten largest holdings make up 17% of its $536B portfolio in Q4 2019.
- JP Morgan Chase opened 374 new positions and closed 490 in Q4 2019.
- JP Morgan Chase's portfolio value rose 6.8% quarter-over-quarter to $536B.
Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.